Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer

BackgroundOvarian cancer has long been known to be the deadliest cancer associated with the female reproductive system. More than 15% of ovarian cancer patients have a defective BRCA-mediated homologous recombination repair pathway that can be therapeutically targeted with PARP inhibitors (PARPi), s...

Full description

Bibliographic Details
Main Authors:	Shicheng Yang, Allen Green, Needa Brown, Alexis Robinson, Merline Senat, Bryanna Testino, Daniela M. Dinulescu, Srinivas Sridhar
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Oncology
Subjects:	sustained delivery PARP inhibitor metastatic ovarian cancer Talazoparib loaded implant BRCA deficient mouse model
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1175617/full

Similar Items

A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer
by: Paige Baldwin, et al.
Published: (2024-03-01)

PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice
by: M. A. Frolova, et al.
Published: (2020-07-01)

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
by: Víctor Albarrán, et al.
Published: (2023-05-01)

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
by: Elizaveta Polyanskaya, et al.
Published: (2023-11-01)

Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer
by: T. Yu. Semiglazova, et al.
Published: (2020-12-01)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
by: Dong Zhou, et al.
Published: (2021-05-01)

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)
by: Ticiana A. Leal, et al.
Published: (2022-11-01)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Albert Jang, et al.
Published: (2020-11-01)

Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review
by: Andrei Kachmazov, et al.
Published: (2022-09-01)

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
by: Ashwin Ragupathi, et al.
Published: (2023-03-01)

BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy
by: Aashish Soni, et al.
Published: (2022-11-01)

Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method
by: Zahra Talebi, et al.
Published: (2023-11-01)

In Silico Investigation of the Molecular Mechanism of PARP1 Inhibition for the Treatment of BRCA-Deficient Cancers
by: Fengqin Yan, et al.
Published: (2023-02-01)

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
by: Alessandra Anna Prete, et al.
Published: (2022-01-01)

PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview
by: Islam Kourampi, et al.
Published: (2023-01-01)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
by: Natalya Maluchenko, et al.
Published: (2022-10-01)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
by: Sayra Dilmac, et al.
Published: (2023-07-01)

Pancreatic Cancer: Beyond Brca Mutations
by: Vincenzo Ricci, et al.
Published: (2022-12-01)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
by: Yosuke Hirotsu, et al.
Published: (2020-05-01)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
by: Isabella Faraoni, et al.
Published: (2018-12-01)

PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer
by: Kristie-Ann Dickson, et al.
Published: (2021-08-01)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
by: Florian G. Klein, et al.
Published: (2021-04-01)

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
by: Ciara S. McNevin, et al.
Published: (2022-09-01)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
by: Stephanie Jonuscheit, et al.
Published: (2021-05-01)

Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients
by: Christina T. Grech, et al.
Published: (2022-09-01)

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical Development
by: Whi-An Kwon
Published: (2024-04-01)

Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple−Negative Breast Cancer Cell Lines
by: Fu Hou Wong, et al.
Published: (2022-08-01)

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
by: Sayeh Saravi, et al.
Published: (2021-09-01)

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis
by: Yanhui Li
Published: (2023-12-01)

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
by: Anthony Gonçalves, et al.
Published: (2020-05-01)

Pharmacologic Induction of BRCAness in <i>BRCA</i>-Proficient Cancers: Expanding PARP Inhibitor Use
by: Rachel Abbotts, et al.
Published: (2022-05-01)

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
by: Marta Castroviejo‐Bermejo, et al.
Published: (2018-12-01)

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges
by: Laetitia Collet, et al.
Published: (2024-03-01)

Detection of <i>BRCA1</i>, and <i>BRCA2</i> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting
by: Taylor Ryan McFarland, et al.
Published: (2022-12-01)

Differential Sensitivity of Germline and Somatic <i>BRCA</i> Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
by: Julie A. Vendrell, et al.
Published: (2023-09-01)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
by: Man Yee Keung, et al.
Published: (2020-03-01)

Avulsion of posterior cruciate ligament (PCL) in an adolescent with open tibial physis fixed with fiberwires
by: Vasudeva Nagashree, et al.
Published: (2022-03-01)

Recent Developments in Nanomedicine for Pediatric Cancer
by: Shicheng Yang, et al.
Published: (2021-04-01)

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor
by: Nora Sahnane, et al.
Published: (2020-12-01)

Never tear us a-PARP: Dealing with DNA lesions during mitosis
by: Pepijn M. Schoonen, et al.
Published: (2018-01-01)